Tag: GlobeNewswire

Targets mid-single-digit organic sales growth and 300 basis points of margin expansion over the next five years

Introduces 2035 ambition to double sales and triple Adjusted EBITDA

Strategy designed to support high-single-digit to double-digit annual shareholder returns over time

OXNARD, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) — Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”), a world leader in sourcing, producing, and distributing fresh Hass avocados, today is hosting its 2026 Investor Day in New York City. Management is presenting the Company’s five-year growth strategy and its ambition to double sales and triple profit by 2035.

After more than four decades of building the global supply network, infrastructure and customer capabilities behind its category leadership, Mission is entering a new chapter focused on generating more growth, earnings and cash flow from its platform. The Company’s largest value-creation initiatives are already underway, including the integration of Calavo Growers, expansion of higher-margin Prepared Foods, and improved utilization of Mission’s asset base.

Management Comments

John Pawlowski, President and Chief Executive Officer of Mission, stated, “Mission was built to lead. Over more than 40 years, we built the modern avocado category and created a platform that would be difficult to replicate. Our next chapter is about fully leveraging that platform and compounding the value we deliver to shareholders by growing faster than our markets, expanding margins, converting more earnings into cash and deploying that cash with discipline.”

“Our growth opportunity is broad and compelling. U.S. avocado remains one of the most durable growth stories in food. International markets offer substantial consumption headroom. Prepared Foods extends our avocado leadership into a higher-margin, growing category, and mango gives us a capital-efficient path to develop the next fresh platform. With Calavo synergies and better utilization of the assets already in place, we believe Mission can become a larger, more productive and higher-return company.”

A Financial Framework Built to Compound

Mission’s five-year plan is built around four connected goals for long-term shareholder value creation:

• Organic sales growth: Grow faster than the markets the Company serves, supporting mid-single-digit organic sales growth over the five-year period.
• Margin expansion: Expand margins by approximately 300 basis points over five years through improved portfolio mix, Calavo synergies, SG&A leverage and greater asset utilization.
• Cash conversion: Convert more than 90% of Adjusted Net Income into free cash flow over time.
• Disciplined capital allocation: Invest in the core business, reduce net leverage (total debt less cash) below 1.5 times Adjusted EBITDA, pursue disciplined M&A and execute opportunistic share repurchases.

Together, these initiatives are expected to support high-single-digit organic Adjusted EBITDA growth over the five-year period. Combined with disciplined M&A and opportunistic share repurchases, the framework is designed to support high-single-digit to double-digit annual shareholder returns over time.

Calavo Integration Progressing

Mission has pooled supply, closed the Temecula operation and established its future-state U.S. distribution footprint. The Company is now advancing network and systems transitions, and will be followed by the integration of remaining operations, including Mexico packing and Prepared Foods.

As announced in its fiscal third quarter 2026 earnings release, Mission increased its annualized synergy target from at least $25 million to more than $30 million. The Company expects a small contribution in the fourth quarter of fiscal 2026 and continues to target the full annualized run rate within 18 months of closing.

Disciplined Capital Allocation

Mission’s capital-allocation priorities are to invest in the core business, reduce net leverage below 1.5 times Adjusted EBITDA, pursue M&A where strategic fit and returns are compelling, and repurchase shares opportunistically. The Company currently has a $100 million share-repurchase authorization, which provides meaningful flexibility.

Bryan Giles, Chief Financial Officer of Mission, stated, “Mission is entering a financially compelling stage, with the majority of the heavy investment required to build our platform behind us and the Calavo acquisition adding scale, new capabilities and a meaningful synergy opportunity.”

“Our five-year framework is designed to grow earnings faster than sales and convert more of those earnings into cash. That should give us greater capacity to reduce leverage, fund high-return growth and return capital when it creates attractive value for shareholders.”

Fiscal 2026 Outlook Reaffirmed

Mission is reaffirming its previously provided outlook for the second half and fourth quarter of fiscal 2026:

• Second-half fiscal 2026 Adjusted EBITDA of $84 million to $88 million, including fourth-quarter Adjusted EBITDA of $52 million to $55 million; and
• Mission Peru exportable volume of 120 million to 130 million pounds in the second half, including 67 million to 77 million pounds in the fourth quarter.

Webcast Information

The 2026 Investor Day will be webcast live beginning at 10:00 a.m. ET today. The webcast, along with the presentation materials, will be accessible in the News & Events section of the Company’s investor relations website at https://investors.missionproduce.com. A replay will be available on the same site following the event.

Non-GAAP Financial Measures

This press release contains the non-GAAP financial measures “Adjusted EBITDA,” “Adjusted Net Income” and “Free Cash Flow.” Management believes these measures provide useful information for analyzing the underlying business results. These measures are not in accordance with, nor are they a substitute for or superior to, the comparable financial measures by generally accepted accounting principles.

Adjusted EBITDA refers to net income before interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, other income (expense), and income (loss) from equity method investees, further adjusted by asset impairment and disposals, farming costs for nonproductive orchards (which represents land lease costs), recognition of deferred ERP costs, transaction advisory costs, and any special, non-recurring, or one-time items such as remeasurements or impairments, and any portion of these items attributable to the noncontrolling interest. Segment adjusted EBITDA refers to, with respect to the applicable segment, net income (loss), before interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, other income (expense), and income (loss) from equity method investees, further adjusted by asset impairment and disposals, farming costs for nonproductive orchards (which represents land lease costs), recognition of deferred ERP costs, transaction advisory and integration costs, amortization of inventory adjustments recognized from business combinations, and any special, non-recurring, or one-time items such as remeasurements or impairments, and any portion of these items attributable to the noncontrolling interest.

Adjusted Net Income refers to net income attributable to Mission Produce, before stock-based compensation expense, unrealized gain (loss) on derivative financial instruments, foreign currency gain (loss), farming costs for nonproductive orchards (which represents land lease costs), recognition of deferred ERP costs, transaction advisory and integration costs, amortization of inventory adjustments and intangible asset recognized from business combinations, further adjusted by any special, non-recurring, or one-time items such as remeasurement, impairment or discrete tax charges that are distortive to results, and tax effects of these items, if any, and the tax-effected impact of these non-GAAP adjustments attributable to noncontrolling interest, allocable to the noncontrolling owners based on their percentage of ownership interest.

Free cash flow refers to cash flow from operations minus capital expenditures.

We have not reconciled our forward-looking non-GAAP financial measures to the most directly comparable GAAP measures in reliance on the “unreasonable efforts” exception in Item 10(e)(1)(i)(B) of Regulation S-K. These measures include our fiscal 2026 Adjusted EBITDA outlook, our fiscal 2035 Adjusted EBITDA ambition, our Adjusted EBITDA growth target, our Free Cash Flow Conversion target and our Net Debt to Adjusted EBITDA target. We cannot provide these reconciliations without unreasonable efforts because we cannot predict with reasonable certainty the amount or timing of certain items. These items include stock-based compensation, unrealized gains and losses on derivative financial instruments, foreign currency gains and losses, asset impairments and disposals, transaction advisory and integration costs and income taxes. They are inherently uncertain, depend on factors outside our control and could be material, individually or in the aggregate, to our GAAP results.

About Mission Produce, Inc.

Mission Produce is a global leader in the worldwide fresh produce industry and the world’s premier supplier of fresh Hass avocados, serving retail, wholesale, and foodservice customers in more than 25 countries. Since 1983, Mission has been dedicated to sourcing, producing, and distributing avocados, building one of the most integrated and diversified avocado supply networks in the world. While avocados remain at the core of its business, Mission also markets and distributes mangos, tomatoes, papayas, value-added prepared foods, including guacamole, and grows blueberries as part of its diversified portfolio. The Company is vertically integrated and has sourcing capabilities across 20+ premium growing regions. With a global distribution network spanning North America, Europe, the United Kingdom, and China, Mission provides a reliable year-round supply of premium products and value-added services, including ripening, bagging, custom packing, and logistics management. For more information, visit www.missionproduce.com.

Forward-Looking Statements

Statements in this press release that are not historical in nature are forward-looking statements that, within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, involve known and unknown risks and uncertainties. Words such as “may”, “will”, “expect”, “intend”, “plan”, “believe”, “seek”, “could”, “estimate”, “judgment”, “targeting”, “should”, “anticipate”, “goal” and variations of these words and similar expressions, are also intended to identify forward-looking statements. The forward-looking statements in this press release address a variety of subjects, including statements about our anticipated future performance, anticipated synergies related our completed acquisition of Calavo, the anticipated future performance of Calavo, and our short-term and long-term assumptions, goals and targets. Many of these assumptions relate to matters that are beyond our control and changing rapidly. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurances that our expectations will be attained. Readers are cautioned that actual results could differ materially from those implied by such forward-looking statements due to a variety of factors, including: reliance on primarily one main product, limitations regarding the supply of fruit, either through purchasing or growing; ; the risks that the businesses of Mission Produce and Calavo will not be integrated successfully or that the integration will be more costly or difficult than expected; the risk that the cost savings and any other synergies from the completed acquisition of Calavo may not be fully realized or may take longer to realize than expected; the risk of underperformance of Calavo’s business; the risk that the credit ratings of the combined company or its subsidiaries may be different from what the companies expect; the risk of adverse reactions or changes to business or employee relationships resulting from the completion of the acquisition of Calavo; fluctuations in the market price of fruit; increasing competition; risks associated with doing business internationally, including Mexican and Peruvian economic, political and/or societal conditions; inflationary pressures; establishment of sales channels and geographic markets; loss of one or more of our largest customers; general economic conditions or downturns; supply chain failures or disruptions; disruption to the supply of reliable and cost-effective transportation; failure to recruit or retain employees, poor employee relations, and/or ineffective organizational structure; inherent farming risks, including climate change; seasonality in operating results; failures associated with information technology infrastructure, system security and cyber risks; new and changing privacy laws and our compliance with such laws; food safety events and recalls; failure to comply with laws and regulations; changes to trade policy and/or export/import laws and regulations; risks from business acquisitions, if any; lack of or failure of infrastructure; material litigation or governmental inquiries/actions; failure to maintain or protect our brand; changes in tax rates or international tax legislation; risks associated with global conflicts; inability to accurately forecast future performance; the viability of an active, liquid, and orderly market for our common stock; volatility in the trading price of our common stock; concentration of control in our executive officers, and directors over matters submitted to stockholders for approval; limited sources of capital appreciation; significant costs associated with being a public company and the allocation of significant management resources thereto; reliance on analyst reports; failure to maintain proper and effective internal control over financial reporting; restrictions on takeover attempts in our charter documents and under Delaware law; the selection of Delaware as the exclusive forum for substantially all disputes between us and our stockholders; risks related to restrictive covenants under our credit facility, which could affect our flexibility to fund ongoing operations, uses of capital and strategic initiatives, and, if we are unable to maintain compliance with such covenants, lead to significant challenges in meeting our liquidity requirements and acceleration of our debt; and other risks and factors discussed from time to time in our Annual and Quarterly Reports on Forms 10-K and 10-Q, the “Risk Factors” in our Proxy Statement/Prospectus dated March 20, 2026 (the “Proxy Statement/Prospectus”), and in our other filings with the Securities and Exchange Commission. You can obtain copies of our SEC filings on the SEC’s website at www.sec.gov. The forward-looking statements contained in this press release are made as of the date hereof and the Corporation does not intend to, nor does it assume any obligation to, update or supplement any forward-looking statements after the date hereof to reflect actual results or future events or circumstances.

Contacts

Investor Relations
Andrew Pearson
Vice President Investor Relations and Strategy
Mission Produce, Inc.
apearson@missionproduce.com

Media
Jenna Aguilera
Director of Communications
Mission Produce, Inc.
press@missionproduce.com

HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) — Skyward Specialty Insurance Group, Inc.^TM (NASDAQ: SKWD) (“Skyward Group” or “the Company”) expects to issue its third quarter 2026 earnings results, inclusive of Apollo Group Holdings Ltd., after the market closes on Thursday, November 5 which will be available on the Company website at investors.skywardinsurance.com/ under Quarterly Results.

Skyward Group will host its earnings call to review the third quarter 2026 financial results on Friday, November 6 at 10:00 a.m. EST.

Investors may access the live audio webcast via the link on the Company’s investor site at investors.skywardinsurance.com/ under Events & Presentations. Additionally, investors can access the earnings call via conference call by registering via the conference link. Users will receive dial-in information and a unique PIN to join the call upon registering.

A webcast replay will be available two hours following the call in the same location on the Company’s investor website.

About Skyward Group

Skyward Group is the holding company brand for its U.S. and Lloyds businesses, Skyward Specialty Insurance Group, Inc.® and Apollo, respectively, delivering a comprehensive suite of specialized insurance solutions across global specialty property and casualty markets. Focused on the specialty industry’s most niche, complex risks of today and the emerging challenges of tomorrow, Skyward Group leverages the forward-looking insight and disciplined execution of each organization to drive sustainable growth and long-term value for its shareholders, distribution partners, and other stakeholders.

For more information about Skyward Group, Skyward Specialty, and Apollo, please visit skywardgroup.com

For investor relations information contact:

Jordan Arnold
JArnold@skywardinsurance.com
346.215.0250

Medical Advisory Board represents another milestone in Nuwellis’ broader pediatric strategy, alongside proposed Aquadex SmartFlow® label expansion seeking to extend to pediatric patients weighing 5 kilograms or more

MINNEAPOLIS, Oct. 08, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to support the continued development of Vivian™, the Company’s next-generation pediatric continuous renal replacement therapy (CRRT) platform. Vivian is under development for children as small as 2.5kg and it incorporates multiple fluid management therapies in one platform.

“Vivian is being purpose-built around the unique clinical and operational needs of pediatric patients and the clinicians who care for them,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “Direct provider and nurse input at this critical stage provides the opportunity to validate the progress we have made and ensure that the voice of the customer continues to shape the system as we move forward. We believe the advisory board is an important development milestone within our pediatric strategy and reflects our commitment to building solutions that address unmet needs across the continuum of care.”

The meeting assembles approximately a dozen pediatric providers, nurses, and clinical advisors representing 11 nationally recognized pediatric institutions across the U.S. for an immersive, hands-on evaluation of the latest Vivian System. The advisory board marks the Company’s first dedicated Vivian Medical & Nursing Advisory Board in several years and represents an important step as Nuwellis advances the system through its next phase of product development.

Feedback from the Medical & Nursing Advisory Board is expected to help Nuwellis validate design decisions, identify unmet clinical and workflow needs, and prioritize future system enhancements. Nuwellis will incorporate insights gathered during the meeting into development priorities and refinements intended to guide Vivian toward its next major program milestones.

The Vivian Medical & Nursing Advisory Board is part of Nuwellis’ broader strategy to strengthen its position in pediatric fluid management and renal support. The Company has built a growing presence in pediatric hospitals using its Aquadex SmartFlow ultrafiltration system and is working through regulatory procedures to is seeking to expand the Aquadex indication to pediatric patients weighing 5 kilograms or more, compared with the system’s current 20-kilogram minimum labeled patient weight.

Together with continued development of Vivian, these initiatives represent a multi-pronged pediatric strategy spanning near-term expansion of Aquadex and longer-term development of a purpose-built pediatric CRRT platform.

About Aquadex
The Aquadex SmartFlow System is currently indicated for the continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ strategy includes expanding its portfolio through internally developed technologies and strategic commercial partnerships that broaden its presence across acute and chronic critical care. For more information, visit www.nuwellis.com.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com

ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310^®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026.

Abstract Title: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial
Session Type: Late-Breaking Science (Oral Presentation)
Session Title: LBS.05 New Frontiers in Cardiometabolic Risk Reduction
Session Date and Time: Monday, November 9, 2026, 8:00 a.m. CST

The accepted abstract titles are available online on the AHA website. The data in the abstract and presentation are embargoed until the date and time of presentation. A copy of the presentation will be available at www.crisprtx.com once the presentation concludes.

About In Vivo Liver Editing Programs

CRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP) delivery platform to enable gene editing in the liver using both CRISPR/Cas9 and its novel, proprietary SyNTase^™ editing technology. The Company’s in vivo portfolio includes three cardiovascular programs: CTX310, targeting angiopoietin-related protein 3 (ANGPTL3), in development for heterozygous and homozygous familial hypercholesterolemia, mixed dyslipidemias, and severe hypertriglyceridemia; CTX340^™, targeting angiotensinogen (AGT), in development for refractory hypertension; and CTX321^™, targeting LPA, in development for patients with elevated lipoprotein(a) [Lp(a)]. In addition, the Company’s disclosed development candidates also include CTX460^™, targeting SERPINA1 using SyNTase editing, for the treatment of alpha-1 antitrypsin deficiency (AATD).

About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY^® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase^™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

CRISPR THERAPEUTICS^® standard character mark and design logo, CTX310^®, CTX321^™, CTX340^™, CTX460^™ and SyNTase^™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY^® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners. 

CRISPR Therapeutics Forward-Looking Statement
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials and expectations regarding data, safety and efficacy generally; (ii) data included in the above-described oral presentation and any associated abstract; and (iii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9, as well as other technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in CRISPR Therapeutics most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Investor Contact:
+1-617-307-7503
ir@crisprtx.com

Media Contact:
+1-617-315-4493
media@crisprtx.com

SciTec’s enhanced data fusion system enables warfighters to improve detection, tracking, and characterization of unmanned aerial threats

*SciTec fused sensor data and mission visualizations supporting the U.S. Air Force’s Cloud‑Based Command and Control (CBC2) system and its newly expanded counter UAS integration

BOULDER, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE) — SciTec, a Firefly Aerospace company, today announced an extension to its Cloud-Based Command and Control (CBC2) contract with the U.S. Department of the Air Force Command, Control, Communications, and Battle Management to integrate a new class of counter unmanned aerial system (CUAS) sensor feeds for the Advanced Battle Management System. The extension adds $1.5 million, bringing the total contract value to $31 million, and expands SciTec’s ongoing efforts to deliver the operational data fusion system that enhances command-and-control warfighting capabilities for mission partners.

Under this contract expansion, SciTec will expand its current data fusion system by adding additional approved counter-UAS sensor data sources. This expanded data layer supports improved situational awareness and decision-making for mission partners.

“This expansion underscores the critical role SciTec’s data fusion system plays in the Cloud-Based Command and Control ecosystem,” said David Simenc, SciTec’s President. “As new mission needs arise, our scalable architecture is already designed to rapidly integrate additional sensors and data types to strengthen warfighter decision making.”

CBC2 remains a central component of the Department of the Air Force Battle Network and supports the Combined Joint All Domain Command and Control vision. By continuously integrating new data sources and tools into the CBC2 system, SciTec and the Air Force are accelerating the pace at which modern battle management capabilities can be delivered to the operational edge.

About SciTec
SciTec, a wholly owned subsidiary of Firefly Aerospace, is a leader in advanced defense technologies. Headquartered in Princeton, N.J., SciTec has more than four decades of experience supporting high-stakes national security missions with AI-enabled defense software and cloud-based, on-premise, and edge processing capabilities. SciTec’s industry-leading software and big data processing capabilities are proven in operations for missile warning and defense; intelligence, surveillance and reconnaissance; space domain awareness; remote sensing and analysis; and autonomous command and control. For more information, visit www.scitec.com.

About Firefly Aerospace
Firefly Aerospace is a space and defense technology company on a mission to reliably and repeatedly launch, land, and operate space systems from Earth to the Moon and beyond. As the partner of choice for responsive space missions, Firefly is the first commercial company to launch a satellite to orbit with approximately 24-hour notice and the first to achieve a successful landing on the Moon. Established in 2017, Firefly’s engineering, manufacturing, and test facilities are co-located in central Texas to enable rapid innovation and vertical integration for the company’s small- to medium-lift launch vehicles, lunar landers, and orbital vehicles. For more information, visit www.fireflyspace.com.

Forward-Looking Statements
This press release contains “forward-looking statements” including, but not limited to, statements regarding total contract value, SciTec’s plans and capabilities, pace of delivery of modern battle management capabilities, and statements of SciTec’s leadership team. These and other statements regarding Firefly’s (and its subsidiary SciTec’s) future expectations, beliefs, plans, objectives, assumptions, or performance that are not historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “modernize,” “may,” “will,” “expands,” “expects,” “plans,” “anticipates,” “could,” “would,” “target,” “intends,” “support,” and “believes.” There may also be negative words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Not all forward-looking statements contain such identifying words. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates, or expectations will be achieved.

Various risks that could cause actual results to differ from those expressed by the forward-looking statements included in this press release include, but are not limited to: disruptions in U.S. government operations, funding, and budgetary or procurement priorities; the fact that U.S. government contracts are generally not fully funded at inception, may be undefinitized, and may be reduced, modified, or terminated, which could prevent us from realizing our backlog; our dependence on a limited number of customers; our inability to comply with our contractual obligations or to meet the eligibility requirements and security-clearance certifications for government contracts; the limitations on disclosure arising from classified contracts; the extensive regulation of defense-industry contracting; a failure of our information technology systems or security protections; our failure to realize the expected benefits of the SciTec acquisition; the fluctuation of our operating results; adverse publicity stemming from any incident involving us, our competitors, or our customers; the failure to adequately protect our proprietary intellectual property rights; and other risk factors set forth in Firefly’s filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. These statements are based on management’s current expectations, assumptions, and beliefs concerning future developments, which are inherently subject to uncertainties, risks, and changes in circumstances that are difficult to predict. We cannot assure you that the events reflected in the forward-looking statements will occur; actual events could differ materially from those described in the forward-looking statements. We undertake no intent or obligation to publicly update or revise any of the estimates and other forward-looking statements made in this announcement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contacts
press@scitec.com
press@fireflyspace.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9fce9fb5-e1e9-43b0-a4ab-45a61b2aa9f1

Trailer is designed to support automated multi-drone spraying and seeding, with automated battery recharging, launch and landing platform, with future adaptations planned for surveying and inspections

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that its ZenaDrone subsidiary has begun building a mobile agricultural drone operations trailer and will begin testing it in the coming months. The trailer is designed to transport and automate precision agriculture Drone as a Service jobs including for drone swarm operations. It is being configured to work with the IQ Octo drone, to complete jobs with minimal human intervention, improving speed and job capacity, and will be adapted to work with other DaaS applications such as surveys and inspection jobs in the future. The IQ Octo is ZenaDrone’s medium-sized, eight-motor autonomous drone currently at the prototype testing stage, built for precision spraying and seeding. Battery powered, it is designed for roughly 20 to 25 minutes of flight per charge and a payload of up to 25 kilograms of liquid or seed, applying fertilizers, crop-protection products, and seed along programmed flight paths.

“Our customers want more acres covered, jobs completed faster, and lower service costs. Developing a mobile operations trailer to support multiple drones, with spraying, seeding, and spreading capabilities and automated battery recharging, is aimed squarely at those needs,” said Shaun Passley, Ph.D., ZenaTech CEO. “We are starting development and testing in precision agriculture, with the goal of extending this approach across our Drone as a Service applications. For ZenaTech’s DaaS business, the opportunity is to serve more customers with each crew and drone fleet, supporting stronger margins and a more scalable service business.”

The trailer is designed as a customizable mobile hub that transports drones and supports field operations, including battery charging, payload replenishment, and autonomous takeoff and landing. Built for compact and road-worthy field operations, it has a retractable top cover and panels for fast drone set up and launch directly from the trailer. It is built to support drone swarms of up to five aircrafts working across precision agriculture jobs, beginning with IQ Octo spraying, seeding, and spreading operations, and can later be adapted for surveying and inspection applications. The trailer is currently in the prototype build-and-test stage at the Company’s facility in Mesa, Arizona where it is expected to be produced.

A mobile operations trailer supporting four to five drones is designed to deliver faster job completion, less downtime, lower operating costs, and greater daily capacity. By bringing spraying, seeding, and spreading supplies directly to the job site with automated refilling, and by recharging batteries without manual intervention, the trailer is designed to keep fleets flying with fewer interruptions and less hands-on servicing. The goal is quicker turnaround and planned lower costs for customers, enabling DaaS operators to cover more acres, complete more jobs, and improve margins from the same fleet.

Drone as a Service (DaaS) is ZenaTech’s model for delivering drone-based automation of legacy or manual jobs, data, and analytics as a recurring service rather than selling drone hardware outright. It is designed to give customers across agriculture, land surveying and construction, industrial inspections and maintenance, power washing of buildings, and other industries access to automated drone capabilities without owning or operating a fleet, while building a scalable, recurring-revenue business for ZenaTech.

The Company will provide further updates as it reaches additional development and testing milestones for the mobile agricultural drone operations trailer.

About ZenaTech

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio under development includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, the IQ Aqua, for underwater applications, and the IQ Octo for precision agriculture. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.

Contacts for more information:

Company, Investors and Media:
Linda Montgomery
ZenaTech
312-241-1415

Investors:
Michael Mason
CORE IR
investors@zenatech.com

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Nano, IQ Square, IQ Quad, IQ Aqua, IQ Octo, IQ Glider, IQ Sphere, ZenaDrone 2000, Interceptor P-1; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech.

SAN JOSE, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) — QuantumScape Corporation (NASDAQ: QS), a global leader in solid-state lithium-metal battery technology, today introduced the QS PowerBlock for AI data centers. The modular system can deliver four times the power density and five times the runtime of current data center industry standards.

The QS PowerBlock brings QS solid-state lithium-metal battery technology into AI data centers, supporting safer, higher-performing energy storage and 800VDC architecture. An adaptable reference design, QS PowerBlock can fit a variety of module, shelf, and rack formats, and is designed for deployment in industry-standard power rack configurations. Paired with advanced power system components, it can provide AI data center customers with a compelling combination of power, runtime, and safety to power the 1 MW racks of next-generation data centers.

In a demonstration using an expected data center training workload, the QS PowerBlock exceeded key specifications set by the Open Compute Project (OCP), the industry consortium that defines open hardware standards for data centers:

• 4x the power density, allowing power-hungry AI systems to integrate into compact and cost-effective data center designs.
• 5x longer runtime, giving data center operators more margin to smooth out power fluctuations and improve hardware productivity.
• Better safety compared to conventional lithium-ion batteries, helping protect billion-dollar infrastructure investments. QS battery cells have demonstrated thermal stability well over 300 °C in third-party and customer safety testing, compared to conventional lithium-ion cells, which typically go into catastrophic thermal runaway at ~180 °C.

“QS solid-state battery technology offers an unmatched combination of energy, power, and safety for many different applications, from electric vehicles to AI data centers and beyond,” said Dr. Siva Sivaram, CEO and president of QS. “With the QS PowerBlock, we are bringing this value proposition to AI data center customers, to enable the 800VDC designs that will power the next phase of AI growth.”

The QS PowerBlock design will be on display at the 2026 OCP Global Summit, October 12–15 at the San Jose Convention Center, at booth C19, hosted by Megmeet, an official partner and power system component provider for the NVIDIA MGX™ Ecosystem.

QS also announced that it has joined the OCP as a member. As AI workloads push data centers toward unprecedented power density, QS is joining industry leaders to build the open standards that infrastructure providers depend on.

The QS PowerBlock performance results were achieved through prototype testing and modeled system configurations under controlled conditions, with comparisons benchmarked against the OCP Open Rack V3 (ORV3) specification. Final QS PowerBlock performance will depend on product design, system configuration and real-world operating conditions.

About QuantumScape Corporation
QuantumScape is on a mission to revolutionize energy storage to enable a sustainable future. The company’s next-generation solid-state lithium-metal battery technology is designed to enable greater energy density, faster charging and enhanced safety to support the transition away from legacy energy sources toward a lower carbon future. For more information, visit www.quantumscape.com.

Forward-Looking Statements
Certain information in this press release may be considered “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the anticipated performance, capabilities and benefits of the QS PowerBlock reference design, its potential deployment in AI data center applications, the commercialization and scaling of its solid-state lithium-metal battery technology, and the application of its technology to AI data centers, automotive and other markets. These forward-looking statements are based on management’s current expectations, assumptions, hopes, beliefs, intentions and strategies regarding future events and are based on currently available information as to the outcome and timing of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements due to various risks, including the successful development and commercialization of our solid-state battery technology, the ability to achieve in commercial products the performance demonstrated in prototype testing and modeled system configurations, dependence on third-party power system components and partners, achieving technical and financial milestones, building out of high-volume processes and otherwise scaling production, achieving the performance, quality, consistency, reliability, safety, cost and throughput required for commercial production and sale, changes in economic and financial conditions, market demand for EVs, AI data centers and other energy storage applications, retaining key personnel, competition, regulatory changes, broader economic conditions, and other factors, including those discussed in the section titled “Risk Factors” in our Annual Report and Quarterly Reports and other documents filed with the Securities and Exchange Commission from time to time. Except as otherwise required by applicable law, the company disclaims any duty to update any forward-looking statements.

Contacts:

For Investors
ir@quantumscape.com

For Media
media@quantumscape.com

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/a52ddd94-f33b-46e1-af41-896054744524

CEO Cameron Chell “See First, Act First: Sensing the Modern Battlespace” Panelist in Washington, D.C.

Washington, DC, Oct. 08, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading developer of drone solutions and systems, today announced that Cameron Chell, President and Chief Executive Officer, will participate in the 2026 Raymond James Aerospace, Defense & Government Services Conference being held today at Nationals Park in Washington, D.C.

Raymond James Financial, Inc. is a diversified financial services firm providing private client, capital markets, asset management, banking and other services to individuals, corporations and institutions. The firm has an established presence across the United States and Canada, as well as operations in the United Kingdom and Europe.

The conference brings together leaders from across the aerospace, defense, government services and technology sectors to discuss emerging capabilities, industry priorities and the evolving national security landscape.

Chell will participate in the panel “See First, Act First: Sensing the Modern Battlespace,” scheduled for 2:00 p.m. to 2:25 p.m. ET. The discussion will examine the evolving sensor-to-decision chain in modern warfare, including the use of artificial intelligence in threat detection and classification, distributed sensing, electronic warfare, command-and-control integration, and the role of human judgment within increasingly autonomous systems.

Chell will be joined by Brad Garber, Chief Strategy Officer of Hidden Level; Chad Kettering, Chief Executive Officer of Herrick Technology Laboratories; and Andrew Maner, Executive Chairman of Protora. The panel will be moderated by Daniel Bilak of Kinstellar.

“Modern defense environments are creating an urgent requirement for systems that can sense, interpret and respond faster while remaining adaptable at the edge,” said Cameron Chell, President and CEO of Draganfly. “We look forward to contributing to the discussion around how unmanned systems, sensors, AI and integrated technologies are changing the way operators build situational awareness and make mission-critical decisions.”

Draganfly representatives will also participate in meetings during the conference with members of the investment and defense communities as the Company continues to advance its position within the North American defense and unmanned systems market.

About Draganfly

Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8) is a leader in cutting-edge drone solutions and software that are transforming industries and serving stakeholders globally. Recognized for innovation and excellence for over 25 years, Draganfly delivers award-winning technology to the public safety, civil, military, agriculture, industrial inspection, security, mapping, and surveying markets. The Company is driven by passion, ingenuity, and a mission to provide efficient solutions and first-class services to customers worldwide, saving time, money, and lives.

For more information, visit www.draganfly.com.

For investor details, visit:
NASDAQ (DPRO)
CSE (DPRO)
FSE (3U8)

Media Contact
Erika Racicot
Email: media@draganfly.com

Company Contact
Cameron Chell
Chief Executive Officer
(306) 955-9907
Email: info@draganfly.com

Retirement removes market-linked conversion exposure as ECGI advances balance sheet optimization strategy focused on eliminating derivative liabilities and potentially dilutive debt

IRVINE, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) — ECGI Holdings, Inc. (OTC: ECGI) today announced that it has fully extinguished a $2.556 million convertible obligation, marking a significant milestone in the company’s ongoing balance sheet optimization strategy focused on eliminating derivative liabilities, reducing potentially dilutive debt and simplifying its capital structure.

The extinguished obligation carried a principal amount of $2.556 million and included market-linked conversion rights tied to ECGI common stock. The obligation has now been terminated in full.

The underlying note permitted principal and accrued interest to be converted into ECGI common stock at a price based on 80% of the lowest traded price during the 10 trading days preceding a conversion. Eliminating the obligation removes that variable-price conversion structure from ECGI’s capital structure and represents another concrete step in management’s effort to eliminate derivative liabilities and reduce exposure to potentially dilutive financing instruments.

“Balance sheet optimization is a major priority as we continue executing ECGI’s broader strategy,” said Jamie Steigerwald, President of ECGI Holdings. “Eliminating this $2.556 million convertible obligation removes a significant market-linked debt instrument and advances our objective of eliminating derivative liabilities and reducing potentially dilutive debt. We are continuing this work alongside the strategic transactions and operating initiatives already underway across ECGI.”

Management’s balance sheet optimization strategy is focused on simplifying ECGI’s capital structure, eliminating derivative liabilities and addressing legacy financing arrangements that can create potential dilution or capital structure uncertainty.

ECGI intends to continue pursuing opportunities to eliminate derivative liabilities and strengthen its capital structure as the company’s strategic and operating initiatives advance. The company expects to provide additional updates upon completion of further material balance sheet optimization milestones.

About ECGI Holdings

ECGI Holdings, Inc. (OTC: ECGI) is a publicly traded holding company pursuing opportunities to build and scale operating businesses in large, evolving markets.

For additional information, please contact us at info@ecgiholdings.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, among other things, statements regarding ECGI’s balance sheet optimization strategy; its intention to eliminate derivative liabilities and reduce potentially dilutive debt; the company’s ability to address additional financing obligations; future capital structure initiatives; strategic transactions and operating initiatives; and anticipated future updates and developments.

These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Such risks include the company’s ability to negotiate, restructure, repay or otherwise resolve existing obligations on acceptable terms; future financing and capital requirements; potential dilution; the accounting treatment and valuation of derivative liabilities and other financial instruments; market conditions; counterparty performance; regulatory and compliance requirements; and other risks described in ECGI’s public disclosures. Readers should not place undue reliance on forward-looking statements. ECGI undertakes no obligation to update such statements except as required by law.

For more information, please contact:
Jamie Steigerwald
jamie@ecgiholdings.com

Investor Relations, Media Relations and Corporate Communications
Investor Relations
jamie@ecgiholdings.com

Media Relations
media@ecgiholdings.com

Corporate Communications
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

SOURCE: ECGI HOLDINGS, INC.

Recognized sales and the full open order book together total $9 million; $1.7 million booked for the fourth quarter

FREDERICK, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology platform through the manufacturing, licensing, servicing, and selling of its SteraMist iHP products and services, today provided a preliminary sales update for the third quarter ended September 30, 2026.

Preliminary revenue for the third quarter of 2026 was $2.5 million, a 27% increase compared with the third quarter of 2025, and sequential revenue increased 13% over the second quarter of 2026.

• $9 Million as of September 30, 2026, in year-to-date recognized revenue plus open order book;
• $1.7 million booked for the fourth quarter of 2026;
• BIT Solution, Mobile Equipment, and Services were all up in comparison to last year’s third quarter;
• Revenue has increased sequentially in each of the past four quarters; and
• Preliminary third-quarter gross margin is also expected to exceed the second quarter level.

Demand is up across the TOMI portfolio — revenue combined with full backlog at the close of the third quarter of 2026 when compared to the full calendar year of 2025: Mobile Equipment Sales are up 107%, Services at 77%, and integrated automated projects reflect an increase of 330%. BIT Solution at the end of 2026 is projected to surpass last year’s total. Together, these results show growth that is not concentrated in a single product line, but spread across equipment, services, and higher-value automated projects.

At the end of the third quarter, the open order book stood at $2.5 million, up from $2.2 million at the close of the second quarter and has held at or above that level even as orders continue to be fulfilled and removed from the book. New orders are replacing completed work and adding to the backlog, which is consistent with the Company’s focus on integrated automated special solutions and support services.

“Third quarter revenue of $2.5 million, up 27% from the same period last year, reflects continued demand across our business,” said E.J. Shane, Chief Operating Officer of TOMI Environmental Solutions, Inc. “With $1.7 million already booked for the fourth quarter, and with recognized sales and our full open order book together totaling $9 million and climbing.”

“As we continue to evaluate potential merger candidates, we are excited about our current position in the marketplace,” said Dr. Halden Shane, Chief Executive Officer and Chairman of the Board of TOMI Environmental Solutions, Inc. “We feel that the fourth quarter will be profitable, and we expect continued profitability into the foreseeable future. We feel our position heading into the final three months of the year puts us on track to hit our $12 million target for the 2026 year provided all the chess pieces fall into place. This is all due to having the best disinfection decontamination technology in the world and the unfettered loyalty from our 16 employees and over 1500 of our determined and decisive clients.”

The Company expects to report its complete third quarter financial results in its Quarterly Report on Form 10-Q.

For more information about SteraMist and TOMI Environmental Solutions, visit SteraMist.com.

About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to preliminary financial results, including preliminary revenue information, estimated open orders, BIT Solution sales, and estimated total integration pipeline, expected revenue growth in 2026 and beyond, TOMI’s products and services to serve the life sciences sector, and the ability to complete delivery of products and services pursuant to purchase orders. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These may include, but are not limited to, our ability to acquire new customers and expands sales; our projected revenue and revenue recognized from anticipated future purchase orders, invoiced orders, and contracts, our ability to maintain and manage growth and generate sales (equipment and consumable), our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT:  
John Nesbett/Zach Nevas
IMS Investor Relations  
tomi@imsinvestorrelations.com